Andrea Cavazzoni is an Associate Professor at the University of Parma, where he conducts research and teaches in the fields of experimental oncology and molecular pathology. His scientific work focuses primarily on non-small-cell lung cancer, pleural mesothelioma, and the biological mechanisms that regulate tumor progression, response to treatment, and the development of resistance to targeted therapies. After earning a bachelor’s degree in Biological Sciences with honors and a Ph.D. in Molecular Biology and Pathology, he pursued a continuous academic career at the University of Parma, holding various research positions over the years until reaching his current position as an associate professor. Throughout his career, he has developed extensive expertise in the study of the major signaling pathways involved in oncogenesis, with a particular focus on EGFR, PI3K/AKT/mTOR, FAK, FGFR, CDK4/6, and, more recently, KRAS and other genomically relevant alterations from a translational perspective. His scientific output includes over 80 publications in international peer-reviewed journals, numerous presentations at national and international conferences, and ongoing participation in competitive research projects funded by public agencies and the pharmaceutical industry. His most recent work focuses on identifying new therapeutic approaches for NSCLC, overcoming drug resistance mechanisms, and studying prognostic and predictive biomarkers useful in clinical practice. In addition to his research, he is actively involved in teaching undergraduate and graduate programs at the University, holding positions in instruction, coordination, and tutoring. He is also engaged in institutional activities, supervising theses and doctoral students, and serving as a scientific reviewer for international journals.
